Insulin-like growth factor (IGF)-binding protein-5-(201-218) region regulates hydroxyapatite and IGF-I binding

American Journal of Physiology - Endocrinology and Metabolism

Volumn 273, Issue 5 36-5, 1997, Pages

  Campbell, Phil G ^a   Andress, Dennis L ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

Bone; Extracellular matrix; Osteoblast

Indexed keywords

GLYCOSAMINOGLYCAN; HEPARIN; HEPARIN BINDING PROTEIN; HYDROXYAPATITE; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C;

ARTICLE; BINDING AFFINITY; EXTRACELLULAR MATRIX; HEPARINIZATION; HORMONE PROTEIN COMPLEX; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION;

EID: 0030657631     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.1997.273.5.e1005     Document Type: Article

References (15)

1. Andress, D. L. Heparin modulates the binding of insulin-like growth factor (IGF) binding protein-5 to a membrane protein in osteoblastic cells. J. Biol. Chem. 270: 28289-28296, 1995.
2. Andress, D. L. Comparison studies of IGFBP-5 binding to osteoblasts and osteoblast-derived extracellular matrix. Prog. Growth Factor Res. 6: 337-344, 1995.
3. Andress, D. L., and R. S. Birnbaum. Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. J. Biol. Chem. 267: 11467-11472, 1992.
4. Andress, D. L., S. M. Loop, J. Zapf, and M. C. Kiefer. Carboxy-truncated insulin-like growth factor binding protein-5 stimulates mitogenesis in osteoblast-like cells. Biochem. Biophys. Res. Commun. 195: 25-30, 1993.
5. Arai, T., A. Arai, W. H. Busby, and D. R. Clemmons. Glycosaminoglycans inhibit degradation of insulin-like growth factor-binding protein-5. Endocrinology 135: 2358-2363, 1994.
6. Arai, T., J. Clarke, A. Parker, W. Busby, Jr., T. Nam, and D. R. Clemmons. Substitution of specific amino acids in insulin-like growth factor (IGF) binding protein-5 alters heparin binding and its change in affinity for IGF-I in response to heparin. J. Biol. Chem. 271: 6099-6106, 1996.
7. Bautista, C. M., D. L. Baylink, and S. Mohan. Isolation of a novel insulin-like growth factor (IGF) binding protein from human bone: a potential candidate for fixing IGF-II in human bone. Biochem. Biophys. Res. Commun. 176: 765-763, 1991.
8. Bautista, C., S. Mohan, and D. J. Baylink. Insulin-like growth factors I and II are present in the skeletal tissues of ten vertebrates. Metabolism 39: 96-100, 1990.
9. Booth, B. A., M. Boes, D. L. Andress, B. L. Dake, M. C. Kiefer, C. Maack, R. J Linhardt, K. Bar, E. E. O. Caldwell, J. Weiler, and R. S. Bar. IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domain. Growth Regul. 5: 1-7, 1995.
10. Campbell, P. G. Localization of the insulin-like growth factor (IGF) and plasmin systems in osteosarcoma cells: mechanism for the utilization of bone matrix IGFs (Abstract). Mol. Biol. Cell. 4: S1694, 1993.
11. 10a. Campbell, P. G., and D. L. Andress. Plasmin degradation of insulin-like growth factor-binding protein-5 (IGFBP-5): regulation by IGFBP-5-(201-218). Am. J. Physiol. 273 (Endocrinol. Metab. 36): E996-E1004, 1997.
12. Campbell, P. G., J. F. Novak, K. Wines, and P. E. Walton. Localization of plasmin activity on osteosarcoma cells: cell surface protolysis of insulin-like growth factor binding proteins. Growth Regul. 3: 95-98, 1993.
13. Campbell, P. G., J. F. Novak, T. B. Yanosick, and J. H. McMaster. Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. Endocrinology 130: 1401-1412, 1992.
14. Campbell, P. G., K. Wines, T. B. Yanosick, and J. F. Novak. Binding and activation of plasminogen on the surface of osteosarcoma cells. J. Cell. Physiol. 159: 1-10, 1994.
15. Canalis, E., T. McCarthy, and M. Centrella. Isolation of growth factors from adult bovine bone. Calcif. Tissue Int. 43: 346-351, 1988.